Table 2.
Association of BALF esRAGE levels with pulmonary function parameters and differential cell counts in BALF (n = 57)
| Variables | rs | P-value |
|---|---|---|
| Pulmonary function parameters | ||
| FVC, % predicted | −0.025 | 0.853 |
| DLco, % predicteda | 0.406 | 0.002* |
| Differential cell counts in BALF | ||
| Total cell, × 104/ml | −0.002 | 0.990 |
| Macrophage, % | 0.060 | 0.667 |
| Macrophage, × 104/ml | 0.016 | 0.907 |
| Lymphocyte, % | 0.125 | 0.369 |
| Lymphocyte, × 104/ml | 0.160 | 0.247 |
| Neutrophil, % | −0.049 | 0.727 |
| Neutrophil, × 104/ml | − 0.022 | 0.877 |
| Eosinophil, % | −0.117 | 0.400 |
| Eosinophil, × 104/ml | −0.063 | 0.650 |
* p < 0.05 Spearman’s rank correlation coefficient
aDLco was measured in 55 of 57 patients with IPF
esRAGE endogenous secretory receptor for advanced glycation end products, BALF bronchoalveolar lavage fluid, DLco diffusing capacity for carbon monoxide, FVC forced vital capacity